- Novartis (NVS) receives approval in Australia for its Bexsero vaccine for protecting infants against MenB, a major cause of meningitis, adding to authorization in Europe. The drug is now licensed in over 30 countries.
- In Australia, Bexsero is approved for children aged two months and older. (PR)
- Meanwhile, Novartis has opened an internal probe into accusations by a former employee in China that she was instructed to bribe doctors by her manager in order to meet sales targets.
From other sites
at Zacks.com (Mar 23, 2015)
at Zacks.com (Mar 18, 2015)
at MarketWatch.com (Mar 6, 2015)
at Zacks.com (Mar 5, 2015)
at Nasdaq.com (Feb 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs